SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy
Status:
Terminated
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of
SAR 1118 within the anterior and posterior chamber of the eye and plasma in subjects
undergoing elective vitrectomy when treated with escalating concentrations of the study drug
for approximately 1 week.